All-cause and cause-specific mortality among users of basal insulins NPH, Detemir, and glargine

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Strandberg, Arto Y ^a,b   Hoti, Fabian J ^c   Strandberg, Timo E ^a,d,e   Christopher, Solomon ^c   Haukka, Jari ^c   Korhonen, Pasi ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Aava Medical Centre   (Finland)

^c EPID Research   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN;

ADULT; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; FEMALE; FINLAND; GASTROINTESTINAL DISEASES; HUMAN; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FINLAND; GASTROINTESTINAL DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; NEOPLASMS; RISK;

EID: 85016690124     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151910     Document Type: Article

References (35)

1. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013; 98: 668–77. doi: 10.1210/jc.2012-3042 23372169
2. Gamble J-M, Simpson SH, Eurich DT, Majumdar SR, Johnson A. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes, Obesity and Metabolism, 2010; 12: 47–53. doi: 10. 1111/j.1463-1326.2009.01125.x 19788429
3. Jing L, Avorn J, Kesselheim AS. Trends in Medicaid reimbursements for insulin from 1991 through 2014. JAMA Int Med 2015; 175.10: 1681–6.
4. Tylee T, Hirsch IB. Costs Associated With Using Different Insulin Preparations. JAMA 2015; 314.7: 665–6 doi: 10.1001/jama.2015.7032 26284715
5. National institute for Health and Clinical Excellence (NICE). Type 2 diabetes, newer agents. Available at: www.nice.org.uk. (Accessed 27Mar2015)
6. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49:2142–8. 11118018
7. Goldman-Levine JD, Lee KW. Insulin detemir–a new basal insulin analog. Ann Pharmacother 2005; 39:502–7. 15657117
8. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23:644–9. 10834424
9. Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ 2014; 349:g5459. doi: 10.1136/bmj. g5459 25274009
10. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008; 81:184–9. doi: 10.1016/j.diabres. 2008.04.007 18495286
11. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007; 9:418–27. 17391170
12. Gissler M, Haukka J. Finnish health and social welfare registers in epidemiological research. Norsk Epidemiologi 2004; 14: 113–120.
13. Lahti R, Penttilä A. The validity of death certificates: routine validation of death certification and its effects on mortality statistics. Forensic Sci Int 2001; 115: 15–32. 11056267
14. Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study. Pharmacoepidem Drug Saf 2013; 22:1326–35.
15. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015; 58, 493–504. doi: 10. 1007/s00125-014-3456-9 25481707
16. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015; 22: 976–83 doi: 10.1097/GME.0000000000000450 25803671
17. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41–55.
18. Rassen JA, Shelar AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidem Dr S 2012; 21(S2): 69–80.
19. Price HI, Agnew MD, Gamble JM. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. BMJ open 2015; 5:e006341. doi: 10. 1136/bmjopen-2014-006341 25762229
20. Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract 2010; 64:1609–1618. doi: 10.1111/j.1742-1241.2010.02520.x 20946269
21. UK Hypoglycemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50:1140–7. 17415551
22. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363:1410–8. doi: 10.1056/ NEJMoa1003795 20925543
23. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK, et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care 2015; 38:316–322. doi: 10.2337/dc14-0920 25492401
24. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577–89. doi: 10.1056/NEJMoa0806470 18784090
25. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53:298–304. doi: 10.1016/j.jacc.2008.10.008 19147051
26. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014; 311(22):2288–2296. doi: 10.1001/jama.2014.4312 24915260
27. Adams KF, Leitzmann MF, Ballard-Barbash R, Albanes D, Harris TB, Hollenbeck A, et al. Body mass and weight change in adults in relation to mortality risk. Am J Epidemiol 2014; 179:135–44. doi: 10. 1093/aje/kwt254 24173550
28. Rossetti P, Porcellati F, Fanelli CG., Perriello G, Torlone E, Bolli GB. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 2008; 114:3–10. doi: 10.1080/13813450801900777 18465353
29. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52:1734–44.
30. Yang X-L, Chan JCN. Diabetes, insulin and cancer risk. World J Diabetes 2012; 3:60–64 doi: 10.4239/ wjd.v3.i4.60 22532884
31. Colmers IN, Bowker SL Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab 2012; 38:485–506. doi: 10.1016/j.diabet.2012.08.011 23159131
32. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New Engl J Med. 2012; 367:319–28. doi: 10. 1056/NEJMoa1203858 22686416
33. Fagot JP, Blotière PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care 2013; 36:294–301. doi: 10.2337/dc12-0506 22966091
34. Dejgaard A, Lynggaard H, Råstam J, Thomsen MK. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009; 52,2507–12. doi: 10.1007/s00125-009-1568-4 19838665
35. Karlstad Ø, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin and insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies. Curr Drug Saf 2014; 8:333–48.